4.1
A systematic review (SR) and meta-analysis included 5 randomised controlled trials (RCTs) of patients (n=703) treated by duckbill-shaped endobronchial valve (EBV) insertion and 3 RCTs of patients (n=372) treated by umbrella-shaped EBV insertion, both compared with standard medical care (SMC). These 2 groups were analysed separately. In a meta-analysis of the 5 RCTs of duckbill EBV insertion compared with SMC, there was a statistically significant difference in 1% change from baseline in forced expiratory volume in 1 second (FEV1) in favour of duckbill EBV insertion (standardised mean difference [SMD] 0.48, 95% confidence interval [CI] 0.32 to 0.64, p<0.00001, I2=42). In 2 RCTs (n=143) from the same meta-analysis, a 2% increase in FEV1 was statistically significantly more frequent in patients treated by duckbill EBV than in those treated by SMC at 90‑day follow-up (SMD 0.77, 95% CI 0.43 to 1.11, p<0.00001, I2 = 0%). In the other 3 RCTs (n=560) from the same meta-analysis, a 2% increase in FEV1 was statistically significantly more frequent in patients treated by duckbill EBV than in those treated by SMC at 6‑month follow-up (SMD 0.40, 95% CI 0.22 to 0.58, p<0.00001, I2=41%). One RCT (n=73), which studied patients treated by the umbrella EBV, reported no statistically significant difference in FEV1 measurements at 3‑month follow-up (MD 0.90 litres, standard deviation [SD] 0.34) compared with patients having SMC (0.87 litres, SD 0.34, p=0.065). A second RCT (n=22) of the umbrella EBV reported statistically significantly improved FEV1 measurements in patients treated unilaterally (21.4%, SD 10.7%) but not in patients treated bilaterally (−3.1%, SD 15.0; MD 24.50%, 95% CI 13.61 to 35.39). The SR reported a statistically significantly larger change in FEV1 from baseline in patients with heterogeneous emphysema treated by duckbill EBV than in patients with homogeneous emphysema having the same treatment (MD 16.36%, 95% CI 9.02 to 23.71, p=0.00001, I2=0%, n=137, 2 RCTs).